REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: RC108 plus Furmonertinib Mesilate TabletsDrug: Furmonertinib Mesilate Tablets Monotherapy
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06962865
- Locations
- 🇨🇳
Binzhou Medical University Hospital, Binzhou, China
🇨🇳The Second Xiangya Hospital Of Central South University, Changsha, China
🇨🇳Changzhou Cancer Hospital, Changzhou, China
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric Carcinoma
- Interventions
- Biological: Tislelizumab+Oxaliplatin+CapecitabineBiological: Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 616
- Registration Number
- NCT06944496
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, BJ-Beijing, China
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: RC148 plus Carboplatin and Paclitaxel/pemetrexed
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06883630
- Locations
- 🇨🇳
Shunde Hospital of Southern Medical University, Foshan, Guangdong, China
🇨🇳Beijing Tiantan Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06642545
- Locations
- 🇨🇳
Cance Hosoltal Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT06549959
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Tianjin People's Hospital, Tianjin, Tianjin, China
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06456567
- Locations
- 🇺🇸
Hemet site, Hemet, California, United States
🇺🇸Menifee site, Menifee, California, United States
🇺🇸Rockford site, Rockford, Illinois, United States
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06456580
- Locations
- 🇺🇸
Orange Site, Orange, California, United States
🇺🇸Lexington Site, Lexington, Kentucky, United States
🇺🇸Foxboro Site, Foxboro, Massachusetts, United States
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
- Conditions
- High-risk Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06378242
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
🇨🇳West China Hospital, Chengdu, Sichuan, China
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06227156
- Locations
- 🇨🇳
The Third Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China